AIM ImmunoTech Inc (STU:HXB2)
€ 0.356 0.002 (0.56%) Market Cap: 18.26 Mil Enterprise Value: 11.88 Mil PE Ratio: 0 PB Ratio: 4.70 GF Score: 40/100

AIM ImmunoTech Inc at SNN Network Virtual Conference Transcript

Aug 03, 2020 / 07:30AM GMT
Release Date Price: €2.4 (-3.23%)
Unidentified Participant

Greetings, and welcome to the AIM ImmunoTech conference. It is now my pleasure to introduce your host, CEO, Tom Equels. Thank you, Mr. Equels, you may begin.

Tom Equels
AIM ImmunoTech Inc. - Executive Vice Chairman, CEO & President

Hello, everyone. I'm Tom Equels, the CEO of AIM ImmunoTech. First of all, I want to thank you for your interest in our company and our products and the work we're doing. And it's especially important in these troubled times that we're in to have support and understanding the advances that we're trying to make, not just in immunology generally, but also in COVID-19.

We're going to address today an update of our COVID-19 work, our ME/CFS chronic fatigue syndrome work, and our work with COVID-19-induced chronic fatigue and especially our core work that we've done over the past two years in establishing numerous Phase 2 and Phase 1/2 clinical trials in immuno-oncology.

I'm also going to go into an update on our Alferon manufacturing. Alferon is our product, which is a natural alpha interferon. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot